Dexamethasone as an adjuvant therapy for anovulatory, normoandrogenic patients during ovulation induction with exogenous gonadotropins.

What Was Tested

Researchers studied Chorionic Gonadotropin and Dexamethasone in this randomized controlled trial publication.

The objective of their study was to explore the effect of dexamethasone (DEX), a highly potent, long-acting glucocorticoid, on the treatment outcome of 74 anovulatory women aged 21 to 29 years, with normal gonadotropins, androgen, and prolactin (PRL) serum levels who failed to conceive on antiestrogen therapy.

Who Took Part

According to the abstract, 74 women were involved.

The age groups tagged for this paper are adults, women only.

The patients received human menopausal gonadotropin/human chorionic gonadotropin (hMG/hCG) for ovulation induction.

How the Study Was Run

The design is described as randomized.

The women were allocated by chance, so the Chorionic Gonadotropin group and the comparison group should start out alike.

The total amount of gonadotropins used, time required for stimulation, percentage of fertilization, serum estradiol levels, pregnancy rate, cumulative pregnancy rate, and abortions were recorded.

What Was Measured

The subject headings attached to it are Abortion, Spontaneous, Adrenal Cortex, Androgens, Anovulation, Chemotherapy, Adjuvant, Chorionic Gonadotropin and Dexamethasone.

What This Means in Plain Language

The paper is a randomized study of Chorionic Gonadotropin and Dexamethasone in 74 women.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1996 (Journal of assisted reproduction and genetics), a journal based in Netherlands.

More context: the related hCG (human chorionic gonadotropin) library page, all human trials.